Enspire DBS Therapy raises $10.3M Series B1 for RESTORE pivotal DBS stroke rehabilitation — Cleveland Clinic backs
Summary
Enspire DBS Therapy raised $10.3M Series B1 on January 13, 2026 led by Genesys Capital with Cleveland Clinic and JobsOhio Ventures. EDEN feasibility published Nature Medicine. RESTORE pivotal enrolling across multiple US centers with interim data mid-2027. DBS of dentate nucleus plus structured rehab for chronic stroke upper-extremity impairment — first pivotal trial of DBS for stroke, no competing approved device therapies.
Why it matters
Cleveland Clinic co-investing with Genesys Capital in a company developing DBS for stroke rehabilitation is the hospital system validation that the clinical community accepts the scientific premise. Cleveland Clinic's neurology and neurosurgery departments are among the most respected in the US — their financial endorsement is the clinical credibility signal that other academic centers will follow when evaluating whether to participate in RESTORE.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial